Dmpk jobs in Boulder

Cogent Biosciences

Who We Are Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within t

Cogent Biosciences

Who We Are: Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent's lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within

Cogent Biosciences

A biotechnology company is seeking a Drug Metabolism and Pharmacokinetics Lead based in Boulder, CO. The role involves providing scientific direction in drug discovery, leading DMPK strategies, and collaborating across teams. The ideal candidate will hold a PhD in a relevant field and possess extens

Cogent Biosciences

Who We Are: Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent's lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within

Who We Are: Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent's lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within

*Who We Are:** Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent's lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found with

Who We Are: Cogent Biosciences is a publicly traded biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within

The Role: This position works with a fast-paced team in Drug Discovery and Development to provide scientific direction and strategy across the DMPK department by being an expert in the design, execution, and interpretation of in vitro ADME and in vivo PK experiments. The successful candidate will ut

The Role: This position works with a fast-paced team in Drug Discovery and Development to provide scientific direction and strategy across the DMPK department by being an expert in the design, execution, and interpretation of in vitro ADME and in vivo PK experiments. The successful candidate will ut